Medicalisation, smoking and e-cigarettes: evidence and implications

Area of Science:

• Public Health
• Behavioral Science
• Addiction Medicine

Background:

• Debate exists regarding the effectiveness of a medical model for reducing smoking-related harm.
• The increasing availability of smoking cessation treatments and the classification of tobacco dependence as a chronic disease fuel this debate.
• Concerns include undermining industry responsibility and fostering a reliance on 'magic bullets' or diminishing personal agency among smokers.

Purpose of the Study:

• To evaluate the impact and limitations of the medicalization of smoking cessation.
• To analyze factors contributing to the modest success of medical approaches in tobacco control.
• To consider the role of e-cigarettes and regulatory developments in the context of smoking cessation.

Main Methods:

• Literature review and synthesis of arguments within the tobacco control field.
• Analysis of the interplay between medical interventions, population-based strategies, and public perceptions of smoking.
• Examination of the efficacy of pharmacotherapies and the evolving role of novel nicotine products.

Main Results:

• The medicalization of smoking is predicted to have limited impact due to a focus on population-level interventions.
• The modest efficacy of current pharmacotherapies and the public's emphasis on willpower and personal responsibility hinder medical approaches.
• E-cigarettes offer an alternative but face potential regulatory limitations for non-therapeutic nicotine use.

Conclusions:

• Medical approaches to smoking cessation face significant limitations despite increased treatment options.
• A combination of factors, including public understanding and the nature of nicotine addiction, restricts the success of medicalization.
• Future tobacco control strategies must consider both therapeutic and non-therapeutic nicotine options, alongside regulatory frameworks.